BLI VS BTAI Stock Comparison

PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceForecastSentimentTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

BLI
10/100

BLI returned -83.56% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.49%, it's performance is below average giving it a grade of 10 of 100.

BTAI
10/100

BTAI returned -75.82% in the last 12 months. Based on SPY's performance of -21.22%, its performance is below average giving it a score of 10 of 100.

Forecast

BLI
75/100

5 analysts offer 12-month price forecasts for BLI. Together, they have an average target of 0, the most optimistic forecast put BLI at 0 within 12-months and the most pessimistic has BLI at 0.

BTAI

"Forecast" not found for BTAI

Sentiment

BLI
62/100

BLI had a bullish sentiment score of 62.13% across Twitter and StockTwits over the last 12 months. It had an average of 5.53 posts, 0.77 comments, and 1.49 likes per day.

BTAI
70/100

BTAI had a bullish sentiment score of 70.30% across Twitter and StockTwits over the last 12 months. It had an average of 36.07 posts, 104.53 comments, and 720.16 likes per day.

Technicals

BLI
11/100

BLI receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

BTAI
50/100

BTAI receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

BLI
10/100

BLI has missed earnings 7 times in the last 20 quarters.

BTAI
10/100

BTAI has missed earnings 11 times in the last 20 quarters.

Profit

BLI
10/100

Out of the last 10 quarters, BLI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

BTAI
10/100

Out of the last 20 quarters, BTAI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BLI
42/100

BLI has had a lower than average amount of volatility over the last 12 months giving it a grade of 42 of 100.

BTAI
55/100

BTAI has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

Analyst Price Targets

BLI

"Analyst Price Targets" not found for BLI

BTAI
81/100

4 analysts offer 12-month price targets for BTAI. Together, they have an average target of 34, the most optimistic target put BTAI at 73 within 12-months and the most pessimistic has BTAI at 4.

All score calculations are broken down here to help you make more informed investing decisions

Berkeley Lights, Inc. Common Stock Summary

Nasdaq / BLI
Healthcare
Biotechnology
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.

BioXcel Therapeutics, Inc. Common Stock Summary

Nasdaq / BTAI
Healthcare
Biotechnology
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.